CoChat
Sign Up
Cited by 437Regulation of Appetite and ObesityPharmacology and Obesity TreatmentAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record, with a small difference in title or year; 21 of the 21 references it cites were found in a registry or an index.

Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects

Open access
Wynne, Katie, Park, Adrian J., Small, Caroline J., Patterson, Michael, Ellis, Sandra M., Murphy, Kevin G., Wren, Alison M., Frost, Gary S., Meeran, Karim, Ghatei, Mohammad A., Bloom, Stephen R.·2005·Diabetes
DOI 10.2337/diabetes.54.8.2390
Open this paper in CoChat — free accountOpen PDF

Abstract

This study investigated the effect of subcutaneously administered oxyntomodulin on body weight in healthy overweight and obese volunteers. Participants self-administered saline or oxyntomodulin subcutaneously in a randomized, double-blind, parallel-group protocol. Injections were self-administered for 4 weeks, three times daily, 30 min before each meal. The volunteers were asked to maintain their regular diet and level of physical exercise during the study period. Subjects’ body weight, energy intake, and levels of adipose hormones were assessed at the start and end of the study. Body weight was reduced by 2.3 ± 0.4 kg in the treatment group over the study period compared with 0.5 ± 0.5 kg in the control group (P = 0.0106). On average, the treatment group had an additional 0.45-kg weight loss per week. The treatment group demonstrated a reduction in leptin and an increase in adiponectin. Energy intake by the treatment group was significantly reduced by 170 ± 37 kcal (25 ± 5%) at the initial study meal (P = 0.0007) and by 250 ± 63 kcal (35 ± 9%) at the final study meal (P = 0.0023), with no change in subjective food palatability. Oxyntomodulin treatment resulted in weight loss and a change in the levels of adipose hormones consistent with a loss of adipose tissue. The anorectic effect was maintained over the 4-week period. Oxyntomodulin represents a potential therapy for obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diabetes.54.8.2390

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

Sorted by citations

Items 301–400 of 437

Related

See all

Metadata

Authors
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., & Bloom, S. R.
Affiliations
  • Hammersmith Hospital (GB)
  • Department of Dietetics, Imperial College Faculty of Medicine, Hammersmith Hospital, London, U.K
ORCID
Venue
Diabetes
Publisher
American Diabetes Association
Published
2005-08-01
Volume
54
Issue
8
Pages
2390-2395
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
DOI
10.2337/diabetes.54.8.2390
OpenAlex
W2154497567
Cited by
435
References
21
Citations by year
2026: 8 · 2025: 10 · 2024: 17 · 2023: 24 · 2022: 10 · 2021: 24 · 2020: 22 · 2019: 16 · 2018: 26 · 2017: 17 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 31 · 2012: 26
FWCI
8.71
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
Wellcome Trust
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
oxyntomodulin, obesity, weight loss, subcutaneous administration, energy intake, leptin, adiponectin, adipose tissue, anorectic effect, palatability, appetite regulation
MeSH terms
Adipose Tissue, Adolescent, Adult, Blood Glucose, Body Composition, Energy Intake, Diet, Double-Blind Method, Eating, Glucagon-Like Peptides, Female, Humans, Injections, Subcutaneous, Insulin, Kinetics, Male, Middle Aged, Obesity, Self Administration, Weight Loss, Exercise, Leptin, Intercellular Signaling Peptides and Proteins, Adiponectin, Oxyntomodulin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review